Tiny tumor clones could guide cancer treatment choices

NCT ID NCT06686342

Recruiting now Knowledge-focused Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study looks at whether growing a patient's cancer cells in the lab (called organoids) can accurately predict which drug will shrink their tumor. Researchers will compare the lab test results with how the patient actually responds to treatment. The goal is to see if this approach can help doctors choose the most effective therapy for each person with recurrent or metastatic head and neck cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Huashan Hospital, Fudan University
ACTIVE_NOT_RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200040, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DRUG SENSITIVE TEST IN VITRO HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENT DERIVED ORGANOID